Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $18.51 and last traded at $17.49, with a volume of 3403236 shares traded. The stock had previously closed at $17.04.
Silverback Therapeutics Stock Down 15.2 %
The business’s 50 day simple moving average is $14.26 and its two-hundred day simple moving average is $11.54. The stock has a market cap of $507.70 million, a P/E ratio of -5.82 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Rocket Lab is the Right Stock for the Right Time
- How to Invest in Insurance Companies: A Guide
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is Forex and How Does it Work?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
